8-KShareholder MattersCorporate ChangesExhibits & Filings

BIOGEN INC. 8-K Report, Bylaw Amendment (Jun 25, 2024)

Filed June 25, 2024For Securities:BIIB

Summary

Biogen Inc. filed an 8-K on June 25, 2024, detailing the outcomes of its 2024 Annual Meeting of Stockholders held on June 20, 2024. The most significant event from an investor perspective was the approval of an amendment to the Company's Certificate of Incorporation to allow for the exculpation of certain company officers, to the extent permitted by Delaware law. This change, which was previously approved by the Board of Directors, aims to provide a layer of protection for officers against certain liabilities. Additionally, the filing provides the final voting results for all proposals presented at the meeting. These included the election of nine directors to the Board, the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024, an advisory vote on executive compensation, and the approval of two equity incentive plans: the 2024 Omnibus Equity Plan and the 2024 Employee Stock Purchase Plan. All proposals received substantial support from stockholders, indicating general alignment with management's decisions and governance.

Key Highlights

  • 1Stockholders approved an amendment to Biogen's Certificate of Incorporation to add an officer exculpation provision, enhancing protection for company officers under Delaware law.
  • 2All nine nominated directors were overwhelmingly elected to the Board of Directors for a one-year term.
  • 3PricewaterhouseCoopers LLP was ratified as Biogen's independent registered public accounting firm for the fiscal year ending December 31, 2024.
  • 4The advisory vote on executive compensation received strong approval from stockholders.
  • 5The Biogen Inc. 2024 Omnibus Equity Plan was approved, allowing for the issuance of equity awards to employees.
  • 6The Biogen Inc. 2024 Employee Stock Purchase Plan was also approved, facilitating employee stock ownership.
  • 7The officer exculpation provision passed with a significant majority of 'Votes For' (103,146,578) compared to 'Votes Against' (16,274,796).

Frequently Asked Questions

The primary change approved was an amendment to Biogen's Amended and Restated Certificate of Incorporation to add an officer exculpation provision. This allows for the exculpation of certain company officers from personal liability for monetary damages in direct or derivative actions, to the maximum extent permitted by Delaware law.

Yes, all proposals presented to the stockholders at the 2024 Annual Meeting received majority approval. This included the election of directors, ratification of the auditor, advisory vote on executive compensation, the officer exculpation amendment, and the adoption of the 2024 Omnibus Equity Plan and the 2024 Employee Stock Purchase Plan.

The officer exculpation provision provides officers with protection against certain personal liabilities, which can be important for attracting and retaining qualified executives. While it aims to limit personal liability for officers in specific circumstances (excluding breaches of the duty of loyalty, acts or omissions not in good faith, intentional misconduct, or knowing violations of law), it does not eliminate all potential liabilities and is subject to the limits of Delaware law. This is a common governance provision in many corporations.

The stockholders ratified the selection of PricewaterhouseCoopers LLP as Biogen's independent registered public accounting firm for the fiscal year ending December 31, 2024. This appointment was overwhelmingly approved by the shareholders.